BR112016026638A2 - - Google Patents
Info
- Publication number
- BR112016026638A2 BR112016026638A2 BR112016026638A BR112016026638A BR112016026638A2 BR 112016026638 A2 BR112016026638 A2 BR 112016026638A2 BR 112016026638 A BR112016026638 A BR 112016026638A BR 112016026638 A BR112016026638 A BR 112016026638A BR 112016026638 A2 BR112016026638 A2 BR 112016026638A2
- Authority
- BR
- Brazil
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461993423P | 2014-05-15 | 2014-05-15 | |
US61/993,423 | 2014-05-15 | ||
PCT/US2015/030464 WO2015175594A1 (en) | 2014-05-15 | 2015-05-13 | Pladienolide pyridine compounds and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016026638A2 true BR112016026638A2 (pt) | 2017-08-15 |
BR112016026638B1 BR112016026638B1 (pt) | 2022-08-02 |
Family
ID=53284528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016026638-2A BR112016026638B1 (pt) | 2014-05-15 | 2015-05-13 | Composto, composição farmacêutica, e, usos de um composto ou sal farmaceuticamente aceitável do mesmo e de uma composição farmacêutica |
Country Status (35)
Country | Link |
---|---|
US (1) | US9481669B2 (pt) |
EP (2) | EP3514154B1 (pt) |
JP (1) | JP6067943B1 (pt) |
KR (2) | KR101710318B1 (pt) |
CN (1) | CN107074827B (pt) |
AR (1) | AR100431A1 (pt) |
AU (1) | AU2015259237B2 (pt) |
BR (1) | BR112016026638B1 (pt) |
CA (1) | CA2947754C (pt) |
CL (1) | CL2016002835A1 (pt) |
CY (1) | CY1121550T1 (pt) |
DK (1) | DK3143016T3 (pt) |
ES (1) | ES2712401T3 (pt) |
HR (1) | HRP20190432T1 (pt) |
HU (1) | HUE041838T2 (pt) |
IL (1) | IL248529B (pt) |
JO (1) | JO3668B1 (pt) |
LT (1) | LT3143016T (pt) |
MA (1) | MA39915B1 (pt) |
ME (1) | ME03417B (pt) |
MX (2) | MX2016014997A (pt) |
MY (1) | MY195081A (pt) |
PE (1) | PE20170384A1 (pt) |
PH (1) | PH12016502249A1 (pt) |
PL (1) | PL3143016T3 (pt) |
PT (1) | PT3143016T (pt) |
RS (1) | RS58400B1 (pt) |
RU (1) | RU2707730C2 (pt) |
SG (1) | SG11201609693XA (pt) |
SI (1) | SI3143016T1 (pt) |
TR (1) | TR201902328T4 (pt) |
TW (1) | TWI634115B (pt) |
UA (1) | UA119458C2 (pt) |
WO (1) | WO2015175594A1 (pt) |
ZA (1) | ZA201607354B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017040526A2 (en) | 2015-09-01 | 2017-03-09 | Eisai R&D Management Co., Ltd. | Splice variants associated with neomorphic sf3b1 mutants |
ES2757174T3 (es) * | 2015-11-18 | 2020-04-28 | Eisai R&D Man Co Ltd | Una forma en estado sólido de compuestos de pladienolida-piridina y procedimientos de uso |
CN110914457A (zh) | 2017-03-15 | 2020-03-24 | 卫材研究发展管理有限公司 | 剪接体突变及其用途 |
CN111727059A (zh) * | 2017-10-31 | 2020-09-29 | 卫材研究发展管理有限公司 | 包含至少一种剪接体调控剂和至少一种选自BCL2抑制剂、BCL2/BCLxL抑制剂和BCLxL抑制剂的抑制剂的组合及其使用方法 |
BR112020020792A2 (pt) | 2018-04-09 | 2021-01-12 | Eisai R&D Management Co., Ltd. | Certos compostos de pladienolida e métodos de uso |
SG11202009907XA (en) * | 2018-04-12 | 2020-11-27 | Eisai R&D Man Co Ltd | Pladienolide derivatives as spliceosome targeting agents for treating cancer |
AU2019279012A1 (en) * | 2018-06-01 | 2020-12-24 | Eisai R&D Management Co., Ltd. | Methods of using splicing modulators |
IL262658A (en) * | 2018-10-28 | 2020-04-30 | Memorial Sloan Kettering Cancer Center | Prevention of age related clonal hematopoiesis and diseases associated therewith |
JP2023553588A (ja) | 2020-11-04 | 2023-12-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 骨髄異形成症候群(mds)のバイオマーカー及びその使用方法 |
WO2022263702A1 (es) * | 2021-06-18 | 2022-12-22 | Universidad de Córdoba | Compuesto para el tratamiento del glioblastoma |
CN113876771B (zh) * | 2021-11-12 | 2022-09-23 | 中国医学科学院基础医学研究所 | 一种靶向pabpc1的小分子药物及其在慢性髓系白血病中的应用 |
WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI311558B (en) | 2001-02-01 | 2009-07-01 | Mercian Corporatio | Novel physiologically active substance |
TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
US7576204B2 (en) | 2002-07-31 | 2009-08-18 | Mercian Corporation | Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same |
CA2494536C (en) | 2002-07-31 | 2011-10-04 | Mercian Corporation | A 12-membered ring macrolide active substance |
AU2003285012A1 (en) | 2002-10-24 | 2004-05-13 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
JP4439401B2 (ja) | 2002-11-29 | 2010-03-24 | メルシャン株式会社 | マクロライド系化合物の製造方法 |
CA2546614A1 (en) | 2003-11-27 | 2005-06-09 | Mercian Corporation | Dna participating in hydroxylation of macrolide compound |
EP1702982B1 (en) | 2003-11-28 | 2010-05-05 | Kanagawa Academy Of Science And Technology | Method of detecting liver cancer, diagnostic for liver cancer and remedy for cancer |
CN1985154A (zh) | 2004-07-02 | 2007-06-20 | 株式会社加一技术 | 组合计量技术 |
WO2006009276A1 (ja) | 2004-07-20 | 2006-01-26 | Eisai R & D Management Co., Ltd. | プラジエノライドの生合成に関与するポリペプチドをコードするdna |
TW200716744A (en) * | 2005-05-26 | 2007-05-01 | Eisai R&D Man Co Ltd | Genetically modified microorganism and process for production of macrolide compound using the microorganism |
WO2007043621A1 (ja) | 2005-10-13 | 2007-04-19 | Eisai R & D Management Co., Ltd. | プラジエノライド b及びプラジエノライド dの全合成方法 |
WO2008111464A1 (ja) * | 2007-03-05 | 2008-09-18 | Eisai R & D Management Co., Ltd. | スプライシング異常を指標とする抗ガン剤の作用検定方法 |
US20080312317A1 (en) | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
-
2015
- 2015-05-13 HU HUE15727125A patent/HUE041838T2/hu unknown
- 2015-05-13 DK DK15727125.5T patent/DK3143016T3/en active
- 2015-05-13 AR ARP150101485A patent/AR100431A1/es unknown
- 2015-05-13 AU AU2015259237A patent/AU2015259237B2/en active Active
- 2015-05-13 ES ES15727125T patent/ES2712401T3/es active Active
- 2015-05-13 MY MYPI2016001944A patent/MY195081A/en unknown
- 2015-05-13 JO JOP/2015/0113A patent/JO3668B1/ar active
- 2015-05-13 US US14/710,687 patent/US9481669B2/en active Active
- 2015-05-13 PL PL15727125T patent/PL3143016T3/pl unknown
- 2015-05-13 CA CA2947754A patent/CA2947754C/en active Active
- 2015-05-13 TR TR2019/02328T patent/TR201902328T4/tr unknown
- 2015-05-13 KR KR1020167016648A patent/KR101710318B1/ko active IP Right Grant
- 2015-05-13 MA MA39915A patent/MA39915B1/fr unknown
- 2015-05-13 UA UAA201612731A patent/UA119458C2/uk unknown
- 2015-05-13 WO PCT/US2015/030464 patent/WO2015175594A1/en active Application Filing
- 2015-05-13 BR BR112016026638-2A patent/BR112016026638B1/pt active IP Right Grant
- 2015-05-13 RS RS20190233A patent/RS58400B1/sr unknown
- 2015-05-13 KR KR1020177004442A patent/KR102146726B1/ko active IP Right Grant
- 2015-05-13 LT LTEP15727125.5T patent/LT3143016T/lt unknown
- 2015-05-13 RU RU2016148887A patent/RU2707730C2/ru active
- 2015-05-13 MX MX2016014997A patent/MX2016014997A/es active IP Right Grant
- 2015-05-13 TW TW104115293A patent/TWI634115B/zh active
- 2015-05-13 EP EP18210019.8A patent/EP3514154B1/en active Active
- 2015-05-13 SG SG11201609693XA patent/SG11201609693XA/en unknown
- 2015-05-13 EP EP15727125.5A patent/EP3143016B1/en active Active
- 2015-05-13 MX MX2020004476A patent/MX2020004476A/es unknown
- 2015-05-13 ME MEP-2019-81A patent/ME03417B/me unknown
- 2015-05-13 PT PT15727125T patent/PT3143016T/pt unknown
- 2015-05-13 CN CN201580025344.0A patent/CN107074827B/zh active Active
- 2015-05-13 SI SI201530641T patent/SI3143016T1/sl unknown
- 2015-05-13 PE PE2016002233A patent/PE20170384A1/es unknown
- 2015-05-13 JP JP2016526218A patent/JP6067943B1/ja active Active
-
2016
- 2016-10-25 ZA ZA2016/07354A patent/ZA201607354B/en unknown
- 2016-10-26 IL IL24852916A patent/IL248529B/en active IP Right Grant
- 2016-11-08 CL CL2016002835A patent/CL2016002835A1/es unknown
- 2016-11-11 PH PH12016502249A patent/PH12016502249A1/en unknown
-
2019
- 2019-02-22 CY CY20191100228T patent/CY1121550T1/el unknown
- 2019-03-04 HR HRP20190432TT patent/HRP20190432T1/hr unknown
Also Published As
Similar Documents
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/05/2015, OBSERVADAS AS CONDICOES LEGAIS |